{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:41:37Z","timestamp":1776872497995,"version":"3.51.2"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40487-025-00356-0","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T14:31:44Z","timestamp":1752676304000},"page":"711-734","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical Outcome of Febrile Neutropenia and Associated Factors Among Adult Patients with Cancer Treated at Ethiopian Oncology Centers: A Retrospective Observational Study"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0723-6804","authenticated-orcid":false,"given":"Samuel Agegnew","family":"Wondm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Getachew Yitayew","family":"Tarekegn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fisseha Nigussie","family":"Dagnew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel Berihun","family":"Dagnew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tilaye Arega","family":"Moges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tirsit Ketsela","family":"Zeleke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mekdes","family":"Kiflu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wubetu Yihunie","family":"Belay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bantayehu Addis","family":"Tegegne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashenafi Kibret","family":"Sendekie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eyayaw Ashete","family":"Belachew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fasil Bayafers","family":"Tamene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"issue":"3","key":"356_CR1","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3892\/mco.2015.524","volume":"3","author":"CJ de Castro","year":"2015","unstructured":"de Castro CJ, Gasc\u00f3n-Vilaplana P, Casas-Fern\u00e1ndez-de Tejerina AM, et al. Epidemiology and characteristics of febrile neutropenia in oncology patients from Spanish tertiary care hospitals: PINNACLE study. Mol Clin Oncol. 2015;3(3):725\u20139.","journal-title":"Mol Clin Oncol"},{"issue":"4","key":"356_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/0300891620927093","volume":"106","author":"AC Tralongo","year":"2020","unstructured":"Tralongo AC, Antonuzzo A, Pronzato P, et al. Management of chemotherapy-induced neutropenia in patients with cancer: 2019 guidelines of the Italian Medical Oncology Association (AIOM). Tumori J. 2020;106(4):273\u201380.","journal-title":"Tumori J"},{"key":"356_CR3","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, De Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol. 2016;27:v111\u20138.","journal-title":"Ann Oncol"},{"issue":"14","key":"356_CR4","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1200\/JCO.2017.77.6211","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update. J Clin Oncol. 2018;36(14):1443\u201353.","journal-title":"J Clin Oncol"},{"issue":"3","key":"356_CR5","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","volume":"90","author":"GH Lyman","year":"2014","unstructured":"Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol. 2014;90(3):190\u20139.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"356_CR6","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1200\/JCO.2012.45.8661","volume":"31","author":"CR Flowers","year":"2013","unstructured":"Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31(6):794\u2013810.","journal-title":"J Clin Oncol"},{"issue":"4","key":"356_CR7","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56\u201393.","journal-title":"Clin Infect Dis"},{"key":"356_CR8","doi-asserted-by":"crossref","unstructured":"Arega B, Woldeamanuel Y, Adane K, Sherif AA, Asrat D. Microbial spectrum and drug-resistance profile of isolates causing bloodstream infections in febrile cancer patients at a referral hospital in Addis Ababa, Ethiopia. Infect Drug Resist. 2018;11:1511\u20139.","DOI":"10.2147\/IDR.S168867"},{"key":"356_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s12094-018-1983-4","volume":"21","author":"A Carmona-Bayonas","year":"2019","unstructured":"Carmona-Bayonas A, Jimenez-Fonseca P, de Castro EM, et al. SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018). Clin Transl Oncol. 2019;21:75\u201386.","journal-title":"Clin Transl Oncol"},{"key":"356_CR10","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s40265-018-0909-3","volume":"78","author":"PM Kasi","year":"2018","unstructured":"Kasi PM, Grothey A. Chemotherapy-induced neutropenia as a prognostic and predictive marker of outcomes in solid-tumor patients. Drugs. 2018;78:737\u201345.","journal-title":"Drugs"},{"issue":"6","key":"356_CR11","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1200\/JOP.2016.019588","volume":"13","author":"E Tai","year":"2017","unstructured":"Tai E, Guy GP, Dunbar A, Richardson LC. Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012. J Oncol Pract. 2017;13(6):e552\u201361.","journal-title":"J Oncol Pract"},{"issue":"10","key":"356_CR12","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258\u201366.","journal-title":"Cancer"},{"key":"356_CR13","doi-asserted-by":"crossref","unstructured":"Zhang Y, Zheng Y, Dong F, et al. Epidemiology of febrile neutropenia episodes with gram-negative bacteria infection in patients who have undergone chemotherapy for hematologic malignancies: a retrospective study of 10\u00a0years\u2019 data from a single center. Infect Drug Resist. 2020;13:903\u201310.","DOI":"10.2147\/IDR.S241263"},{"key":"356_CR14","first-page":"1151","volume":"19","author":"S Ahn","year":"2011","unstructured":"Ahn S, Lee Y-S, Chun Y-H, et al. Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia. Support Care Cancer. 2011;19:1151\u20138.","journal-title":"Support Care Cancer"},{"key":"356_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.critrevonc.2017.11.005","volume":"120","author":"Y Lalami","year":"2017","unstructured":"Lalami Y, Klastersky J. Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: an overview about well-established and recently emerging clinical data. Crit Rev Oncol Hematol. 2017;120:163\u201379.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"356_CR16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/hon.2040","volume":"31","author":"JJ Lynn","year":"2013","unstructured":"Lynn JJ, Chen KF, Weng YM, Chiu TF. Risk factors associated with complications in patients with chemotherapy-induced febrile neutropenia in emergency department. Hematol Oncol. 2013;31(4):189\u201396.","journal-title":"Hematol Oncol"},{"issue":"5","key":"356_CR17","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1200\/JCO.2014.57.2347","volume":"33","author":"A Carmona-Bayonas","year":"2015","unstructured":"Carmona-Bayonas A, Jim\u00e9nez-Fonseca P, Virizuela Echaburu J, et al. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study. J Clin Oncol. 2015;33(5):465\u201371.","journal-title":"J Clin Oncol"},{"key":"356_CR18","first-page":"1299","volume":"16","author":"R Pettengell","year":"2008","unstructured":"Pettengell R, Schwenkglenks M, Leonard R, et al. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer. 2008;16:1299\u2013309.","journal-title":"Support Care Cancer"},{"issue":"23","key":"356_CR19","doi-asserted-by":"publisher","first-page":"5555","DOI":"10.1002\/cncr.25332","volume":"116","author":"GH Lyman","year":"2010","unstructured":"Lyman GH, Michels SL, Reynolds MW, Barron R, Tomic KS, Yu J. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer. 2010;116(23):5555\u201363.","journal-title":"Cancer"},{"issue":"7","key":"356_CR20","doi-asserted-by":"publisher","first-page":"882","DOI":"10.6004\/jnccn.2016.0093","volume":"14","author":"LR Baden","year":"2016","unstructured":"Baden LR, Swaminathan S, Angarone M, et al. Prevention and treatment of cancer-related infections, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2016;14(7):882\u2013913.","journal-title":"J Natl Compr Cancer Netw"},{"key":"356_CR21","unstructured":"Girma T. Assessment of the management of neutropenic fever in adult patients with hematologic malignancies at Tikur Anbessa Specialized Hospital. Addis Ababa University; 2017."},{"key":"356_CR22","doi-asserted-by":"publisher","first-page":"205031212210982","DOI":"10.1177\/20503121221098236","volume":"10","author":"S Agegnew Wondm","year":"2022","unstructured":"Agegnew Wondm S, Dagnew EM, Tadesse Abegaz S, Kiflu M, Kebede B. Burden, risk factors, and management of neutropenic fever among solid cancer patients in Ethiopia. SAGE Open Med. 2022;10:20503121221098236.","journal-title":"SAGE Open Med"},{"key":"356_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-019-5612-6","volume":"19","author":"BT Deressa","year":"2019","unstructured":"Deressa BT, Cihoric N, Badra EV, Tsikkinis A, Rauch D. Breast cancer care in northern Ethiopia\u2014cross-sectional analysis. BMC Cancer. 2019;19:1\u20136.","journal-title":"BMC Cancer"},{"issue":"6","key":"356_CR24","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.3390\/ijerph20065218","volume":"20","author":"M Azage","year":"2023","unstructured":"Azage M, Zewudie S, Goedert MH, Hagos EG. Epidemiological characteristics of cancer patients attending at Felege Hiwot Referral Hospital, Northwest Ethiopia. Int J Environ Res Public Health. 2023;20(6):5218.","journal-title":"Int J Environ Res Public Health"},{"issue":"17","key":"356_CR25","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.3390\/jcm12175635","volume":"12","author":"H Shmuely","year":"2023","unstructured":"Shmuely H, Monely L, Shvidel L. All-cause mortality and its predictors in haemato-oncology patients with febrile neutropenia. J Clin Med. 2023;12(17):5635.","journal-title":"J Clin Med"},{"issue":"16","key":"356_CR26","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","volume":"18","author":"J Klastersky","year":"2000","unstructured":"Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18(16):3038\u201351.","journal-title":"J Clin Oncol"},{"key":"356_CR27","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.12659\/MSM.892269","volume":"20","author":"M G\u00fcnalp","year":"2014","unstructured":"G\u00fcnalp M, Koyuno\u011flu M, G\u00fcrler S, et al. Independent factors for prediction of poor outcomes in patients with febrile neutropenia. Med Sci Monit. 2014;20:1826.","journal-title":"Med Sci Monit"},{"issue":"2","key":"356_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229828","volume":"15","author":"O Peyrony","year":"2020","unstructured":"Peyrony O, Gerlier C, Barla I, Ellouze S, Legay L, Azoulay E, et al. Antibiotic prescribing and outcomes in cancer patients with febrile neutropenia in the emergency department. PLoS ONE. 2020;15(2): e0229828.","journal-title":"PLoS ONE"},{"key":"356_CR29","unstructured":"Hatamabadi H, Dolatabadi AA, Akhavan A, Safari S. Clinical characteristics and associated factors of mortality in febrile neutropenia patients; a cross sectional study. Arch Acad Emerg Med. 2019;7(1):39."},{"key":"356_CR30","unstructured":"Health UDo, Services H. Common terminology criteria for adverse events (CTCAE). 2017."},{"issue":"2","key":"356_CR31","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/sj.bjc.6600724","volume":"88","author":"I Ray-Coquard","year":"2003","unstructured":"Ray-Coquard I, Borg C, Bachelot T, et al. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer. 2003;88(2):181\u20136.","journal-title":"Br J Cancer"},{"key":"356_CR32","unstructured":"World Health Organization. A healthy lifestyle-WHO recommendations. Eri\u015fim tarihi. 2010;1."},{"issue":"5","key":"356_CR33","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"6","key":"356_CR34","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649\u201355.","journal-title":"Am J Clin Oncol"},{"issue":"10","key":"356_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0224299","volume":"14","author":"RL Parodi","year":"2019","unstructured":"Parodi RL, Lagrutta M, Tortolo M, et al. A multicenter prospective study of 515 febrile neutropenia episodes in Argentina during a 5-year period. PLoS ONE. 2019;14(10):e0224299.","journal-title":"PLoS ONE"},{"key":"356_CR36","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ijregi.2021.09.002","volume":"1","author":"C Sereeaphinan","year":"2021","unstructured":"Sereeaphinan C, Kanchanasuwan S, Julamanee J. Mortality-associated clinical risk factors in patients with febrile neutropenia: a retrospective study. IJID Reg. 2021;1:5\u201311.","journal-title":"IJID Reg"},{"issue":"12","key":"356_CR37","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.apjtb.2015.09.014","volume":"5","author":"M G\u00f6r\u00fck","year":"2015","unstructured":"G\u00f6r\u00fck M, Dal MS, Dal T, et al. Evaluation of febrile neutropenic patients hospitalized in a hematology clinic. Asian Pac J Trop Biomed. 2015;5(12):1051\u20134.","journal-title":"Asian Pac J Trop Biomed"},{"issue":"2","key":"356_CR38","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cncr.11882","volume":"100","author":"J Crawford","year":"2004","unstructured":"Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100(2):228\u201337.","journal-title":"Cancer"},{"key":"356_CR39","unstructured":"Ferdu E. Clinical, laboratory, treatment profiles and outcome of neutropenic fever among high-risk hematologic patients in Tikur Anbessa specialized hospital. 2019."},{"issue":"1","key":"356_CR40","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13027-023-00533-8","volume":"18","author":"LC Safari","year":"2023","unstructured":"Safari LC, Mloka D, Minzi O, Dharsee NJ, Reuben R. Prevalence of blood stream infections and associated factors among febrile neutropenic cancer patients on chemotherapy at Ocean Road Cancer Institute, Tanzania. Infect Agents Cancer. 2023;18(1):52.","journal-title":"Infect Agents Cancer"},{"issue":"1","key":"356_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12941-024-00703-5","volume":"23","author":"A Shelke","year":"2024","unstructured":"Shelke A, Priya P, Mishra S, et al. Investigation of antimicrobial susceptibility patterns, risk factors and their impact on mortality in cancer patients at a tertiary care cancer hospital\u2014a prospective study. Ann Clin Microbiol Antimicrob. 2024;23(1):59.","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"03","key":"356_CR42","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4103\/0971-5851.190352","volume":"37","author":"KG Babu","year":"2016","unstructured":"Babu KG, Lokanatha D, Lakshmaiah K, et al. Bloodstream infections in febrile neutropenic patients at a tertiary cancer institute in South India: a timeline of clinical and microbial trends through the years. Indian J Med Paediatr Oncol. 2016;37(03):174\u201382.","journal-title":"Indian J Med Paediatr Oncol"},{"key":"356_CR43","doi-asserted-by":"crossref","unstructured":"De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses study group (EORTC\/MSG) consensus group. Clin Infect Dis. 2008;46(12):1813\u201321.","DOI":"10.1086\/588660"},{"key":"356_CR44","doi-asserted-by":"publisher","first-page":"v252","DOI":"10.1093\/annonc\/mdq196","volume":"21","author":"J De Naurois","year":"2010","unstructured":"De Naurois J, Novitzky-Basso I, Gill M, Marti FM, Cullen M, Roila F. Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol. 2010;21:v252\u20136.","journal-title":"Ann Oncol"},{"issue":"04","key":"356_CR45","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3855\/jidc.9720","volume":"12","author":"S \u00c7eken","year":"2018","unstructured":"\u00c7eken S, Iskender G, Gedik H, et al. Risk factors for bloodstream infections due to extended-spectrum \u03b2-lactamase producing Enterobacteriaceae in cancer patients. J Infect Dev Ctries. 2018;12(04):265\u201372.","journal-title":"J Infect Dev Ctries"},{"issue":"1","key":"356_CR46","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12879-023-08058-6","volume":"23","author":"N Joudeh","year":"2023","unstructured":"Joudeh N, Sawafta E, Abu Taha A, et al. Epidemiology and source of infection in cancer patients with febrile neutropenia: an experience from a developing country. BMC Infect Dis. 2023;23(1):106.","journal-title":"BMC Infect Dis"},{"issue":"8","key":"356_CR47","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1086\/428732","volume":"40","author":"S Reuter","year":"2005","unstructured":"Reuter S, Kern WV, Sigge A, et al. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis. 2005;40(8):1087\u201393.","journal-title":"Clin Infect Dis"},{"key":"356_CR48","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10096-005-1278-x","volume":"24","author":"W Kern","year":"2005","unstructured":"Kern W, Klose K, Jellen-Ritter A, et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis. 2005;24:111\u20138.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"12_Part_1","key":"356_CR49","doi-asserted-by":"publisher","first-page":"979","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00008","volume":"142","author":"A Gafter-Gvili","year":"2005","unstructured":"Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med. 2005;142(12_Part_1):979\u201395.","journal-title":"Ann Intern Med"},{"issue":"28","key":"356_CR50","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33(28):3199\u2013212.","journal-title":"J Clin Oncol"},{"key":"356_CR51","doi-asserted-by":"crossref","unstructured":"Mhaskar R, Clark OAC, Lyman G, Botrel TEA, Paladini LM, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev. 2014;(10).","DOI":"10.1002\/14651858.CD003039.pub2"},{"issue":"9","key":"356_CR52","first-page":"3","volume":"3","author":"N Hosiriluck","year":"2015","unstructured":"Hosiriluck N, Klomjit S, Rassameehiran S, Sutamtewagul G, Tijani L, Radhi S. Prognostic factors for mortality with febrile neutropenia in hospitalized patients. Southwest Respir Crit Care Chron. 2015;3(9):3\u201313.","journal-title":"Southwest Respir Crit Care Chron"},{"issue":"3","key":"356_CR53","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.diagmicrobio.2009.02.008","volume":"64","author":"M Tumbarello","year":"2009","unstructured":"Tumbarello M, Spanu T, Caira M, et al. Factors associated with mortality in bacteremic patients with hematologic malignancies. Diagn Microbiol Infect Dis. 2009;64(3):320\u20136.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"356_CR54","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10096-003-0894-6","volume":"22","author":"E Velasco","year":"2003","unstructured":"Velasco E, Byington R, Martins C, Schirmer M, Dias L, Gon\u00e7alves V. Prospective evaluation of the epidemiology, microbiology, and outcome of bloodstream infections in hematologic patients in a single cancer center. Eur J Clin Microbiol Infect Dis. 2003;22:137\u201343.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"356_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6963-14-162","volume":"14","author":"T Perron","year":"2014","unstructured":"Perron T, Emara M, Ahmed S. Time to antibiotics and outcomes in cancer patients with febrile neutropenia. BMC Health Serv Res. 2014;14:1\u20137.","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"356_CR56","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.7314\/APJCP.2013.14.2.1115","volume":"14","author":"J Chindaprasirt","year":"2013","unstructured":"Chindaprasirt J, Wanitpongpun C, Limpawattana P, et al. Mortality, length of stay, and cost associated with hospitalized adult cancer patients with febrile neutropenia. Asian Pac J Cancer Prev. 2013;14(2):1115\u20139.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"356_CR57","first-page":"2183179","volume":"2018","author":"SJ Lee","year":"2018","unstructured":"Lee SJ, Kim JH, Han SB, Paik JH, Durey A. Prognostic factors predicting poor outcome in cancer patients with febrile neutropenia in the emergency department: usefulness of qSOFA. J Oncol. 2018;2018(1):2183179.","journal-title":"J Oncol"},{"issue":"20","key":"356_CR58","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.3390\/cells11203314","volume":"11","author":"A-K Lederer","year":"2022","unstructured":"Lederer A-K, Bartsch F, Moehler M, Ga\u00dfmann P, Lang H. Morbidity and mortality of neutropenic patients in visceral surgery: a narrative review. Cells. 2022;11(20):3314.","journal-title":"Cells"},{"issue":"4","key":"356_CR59","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s11605-018-04081-0","volume":"23","author":"JS Jolissaint","year":"2019","unstructured":"Jolissaint JS, Harary M, Saadat LV, et al. Timing and outcomes of abdominal surgery in neutropenic patients. J Gastrointest Surg. 2019;23(4):643\u201350.","journal-title":"J Gastrointest Surg"},{"issue":"08","key":"356_CR60","doi-asserted-by":"publisher","first-page":"886","DOI":"10.3855\/jidc.12520","volume":"14","author":"S \u00c7eken","year":"2020","unstructured":"\u00c7eken S, Gedik H, Iskender G, et al. Evaluation of risk factors for mortality in febrile neutropenia. J Infect Dev Ctries. 2020;14(08):886\u201392.","journal-title":"J Infect Dev Ctries"},{"issue":"9","key":"356_CR61","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1002\/cam4.2955","volume":"9","author":"T Aagaard","year":"2020","unstructured":"Aagaard T, Reekie J, J\u00f8rgensen M, et al. Mortality and admission to intensive care units after febrile neutropenia in patients with cancer. Cancer Med. 2020;9(9):3033\u201342.","journal-title":"Cancer Med"},{"issue":"Suppl 8","key":"356_CR62","first-page":"S53","volume":"99","author":"B Weerasubpong","year":"2016","unstructured":"Weerasubpong B, Makruasi N, Linasmita P, Rattanamongkolgul S. Factors associated with survival outcomes of febrile neutropenia in hematologic malignancy patients. J Med Assoc Thai. 2016;99(Suppl 8):S53\u2013S62.","journal-title":"J Med Assoc Thai"},{"issue":"10","key":"356_CR63","first-page":"2741","volume":"18","author":"AH Osmani","year":"2017","unstructured":"Osmani AH, Jabbar AA, Gangwani MK, Hassan B. Outcomes of high risk patients with febrile neutropenia at a tertiary care center. Asian Pac J Cancer Prev. 2017;18(10):2741.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"5","key":"356_CR64","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1128\/AAC.50.5.1715-1720.2006","volume":"50","author":"DJ Anderson","year":"2006","unstructured":"Anderson DJ, Engemann JJ, Harrell LJ, Carmeli Y, Reller LB, Kaye KS. Predictors of mortality in patients with bloodstream infection due to ceftazidime-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother. 2006;50(5):1715\u201320.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"356_CR65","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1128\/AAC.01509-06","volume":"51","author":"M Tumbarello","year":"2007","unstructured":"Tumbarello M, Sanguinetti M, Montuori E, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother. 2007;51(6):1987\u201394.","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl_1","key":"356_CR66","doi-asserted-by":"publisher","first-page":"i14","DOI":"10.1093\/jac\/dkp075","volume":"63","author":"J Klastersky","year":"2009","unstructured":"Klastersky J. Why empirical therapy? J Antimicrob Chemother. 2009;63(suppl_1):i14\u20135.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"356_CR67","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/CCM.0b013e31822b50c2","volume":"40","author":"M Legrand","year":"2012","unstructured":"Legrand M, Max A, Peigne V, et al. Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med. 2012;40(1):43\u20139.","journal-title":"Crit Care Med"},{"issue":"4","key":"356_CR68","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.tcmj.2011.09.002","volume":"23","author":"K-P Huang","year":"2011","unstructured":"Huang K-P, Wang T-F, Chu S-C, Wu Y-F, Wang R-Y, Kao R-H. Analysis of pathogens and susceptibility in cancer patients with febrile neutropenia and bacteremia: experience in a single institution in eastern Taiwan. Tzu Chi Med J. 2011;23(4):115\u20138.","journal-title":"Tzu Chi Med J"},{"issue":"1","key":"356_CR69","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1365-2141.2005.05845.x","volume":"132","author":"M N\u00f8rgaard","year":"2006","unstructured":"N\u00f8rgaard M, Larsson H, Pedersen G, Sch\u00f8nheyder HC, Rothman KJ, S\u00f8rensen HT. Short-term mortality of bacteraemia in elderly patients with haematological malignancies. Br J Haematol. 2006;132(1):25\u201331.","journal-title":"Br J Haematol"},{"issue":"17","key":"356_CR70","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1001\/archinte.168.17.1897","volume":"168","author":"J Rodr\u00edguez-Ba\u00f1o","year":"2008","unstructured":"Rodr\u00edguez-Ba\u00f1o J, Alcal\u00e1 JC, Cisneros JM, et al. Community infections caused by extended-spectrum \u03b2-lactamase\u2013producing Escherichia coli. Arch Intern Med. 2008;168(17):1897\u2013902.","journal-title":"Arch Intern Med"},{"key":"356_CR71","doi-asserted-by":"publisher","first-page":"117955492412813","DOI":"10.1177\/11795549241281330","volume":"18","author":"J Dimitrijevi\u0107","year":"2024","unstructured":"Dimitrijevi\u0107 J, \u010calama\u0107 M, \u0110urmez O, Krsti\u0107 D, Stojanovi\u0107 M. Serum albumin as a prognostic biomarker for febrile neutropenia outcome and complications: a prospective observational trial. Clin Med Insights Oncol. 2024;18:11795549241281330.","journal-title":"Clin Med Insights Oncol"},{"key":"356_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2891-9-69","volume":"9","author":"D Gupta","year":"2010","unstructured":"Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010;9:1\u201316.","journal-title":"Nutr J"},{"key":"356_CR73","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00277-009-0841-4","volume":"89","author":"JE Kim","year":"2010","unstructured":"Kim JE, Yoo C, Lee DH, Kim S-W, Lee J-S, Suh C. Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma. Ann Hematol. 2010;89:391\u20137.","journal-title":"Ann Hematol"},{"issue":"4","key":"356_CR74","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/SLA.0b013e318230646a","volume":"254","author":"E Slattery","year":"2011","unstructured":"Slattery E, Patchett S. Albumin as a marker of nutrition: a common pitfall. Ann Surg. 2011;254(4):667\u20138.","journal-title":"Ann Surg"},{"key":"356_CR75","doi-asserted-by":"crossref","unstructured":"Cao Y, Su Y, Guo C, He L, Ding N. Albumin level is associated with short-term and long-term outcomes in sepsis patients admitted in the ICU: a large public database retrospective research. Clin Epidemiol. 2023;15:263\u201373.","DOI":"10.2147\/CLEP.S396247"},{"key":"356_CR76","doi-asserted-by":"crossref","unstructured":"Akirov A, Masri-Iraqi H, Atamna A, Shimon I. Low albumin levels are associated with mortality risk in hospitalized patients. Am J Med. 2017;130(12):1465.e11\u2013.e19.","DOI":"10.1016\/j.amjmed.2017.07.020"},{"issue":"2","key":"356_CR77","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1200\/JCO.1996.14.2.636","volume":"14","author":"J Blay","year":"1996","unstructured":"Blay J, Chauvin F, Le Cesne A, et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol. 1996;14(2):636\u201343.","journal-title":"J Clin Oncol"},{"issue":"1","key":"356_CR78","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/s41598-022-25970-0","volume":"13","author":"EJ Cho","year":"2023","unstructured":"Cho EJ, Jeong S-M, Chung GE, et al. Gamma-glutamyl transferase and risk of all-cause and disease-specific mortality: a nationwide cohort study. Sci Rep. 2023;13(1):1751.","journal-title":"Sci Rep"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00356-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-025-00356-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00356-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T12:44:42Z","timestamp":1757249082000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-025-00356-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["356"],"URL":"https:\/\/doi.org\/10.1007\/s40487-025-00356-0","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"assertion":[{"value":"26 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Samuel Agegnew Wondm, Getachew Yitayew Tarekegn, Fisseha Nigussie Dagnew, Samuel Berihun Dagnew, Tilaye Arega Moges, Tirsit Ketsela Zeleke, Mekdes Kiflu, Wubetu Yihunie Belay, Bantayehu Addis Tegegne, Ashenafi Kibret Sendekie, Eyayaw Ashete Belachew, and Fasil Bayafers Tamene have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethical approval (ethical approval eode SoP\/133\/2021) was obtained from the ethical review committee of the Department of Clinical Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar. Informed consent was waived by the review committee of the Department of Clinical Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar because the study was conducted retrospectively and it was difficult to contact the patients directly. Permission to access patient medical records was obtained from UoGCSH and FHCSH clinical directors. Confidentiality was maintained and sufficiently anonymized, and the study was conducted according to the Declaration of Helsinki and the International Council on Harmonization guidelines for good clinical practice.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}